A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn whether apixaban is well-tolerated and acceptable as
anticoagulant therapy, when administered to patients with advanced or metastatic cancer and
at increased risk for venous thromboembolic events. Demonstration of a favorable benefit:risk
profile could lead to significant reduction in this serious and sometimes fatal complication
of ongoing cancer and its treatment.